Xencor

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Xencor and other ETFs, options, and stocks.

About XNCR

Xencor, Inc. is a biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. 

CEO
Bassil I. Dahiyat
CEOBassil I. Dahiyat
Employees
250
Employees250
Headquarters
Pasadena, California
HeadquartersPasadena, California
Founded
1997
Founded1997
Employees
250
Employees250

XNCR Key Statistics

Market cap
1.20B
Market cap1.20B
Price-Earnings ratio
-9.45
Price-Earnings ratio-9.45
Dividend yield
Dividend yield
Average volume
759.55K
Average volume759.55K
High today
$17.18
High today$17.18
Low today
$16.45
Low today$16.45
Open price
$16.72
Open price$16.72
Volume
872.52K
Volume872.52K
52 Week high
$25.54
52 Week high$25.54
52 Week low
$6.92
52 Week low$6.92

Stock Snapshot

With a market cap of 1.2B, Xencor(XNCR) trades at $16.79. The stock has a price-to-earnings ratio of -9.45.

During the trading session on 2025-12-16, Xencor(XNCR) shares reached a daily high of $17.18 and a low of $16.45. At a current price of $16.79, the stock is +2.1% higher than the low and still -2.3% under the high.

Trading volume for Xencor(XNCR) stock has reached 872.52K, versus its average volume of 759.55K.

Over the past 52 weeks, Xencor(XNCR) stock has traded between a high of $25.54 and a low of $6.92.

Over the past 52 weeks, Xencor(XNCR) stock has traded between a high of $25.54 and a low of $6.92.

XNCR News

Simply Wall St 4d
Assessing Xencor Valuation After New U.S. Patent Extends Ultomiris Royalty Stream

Xencor (XNCR) just secured a new U.S. patent that effectively adds about three extra years to its Ultomiris royalty stream, a material boost that could help smo...

Assessing Xencor Valuation After New U.S. Patent Extends Ultomiris Royalty Stream
Simply Wall St 7d
Xencor Is Up 7.1% After Ultomiris Royalty Patent Extension - What's Changed

Xencor, Inc. recently announced that the U.S. Patent and Trademark Office issued U.S. Patent 12,492,253, extending protection for its Xtend Fc domain used to pr...

Xencor Is Up 7.1% After Ultomiris Royalty Patent Extension - What's Changed
TipRanks 7d
Xencor issued U.S. patent for Xtend Fc domain

Xencor (XNCR) announced the issuance of U.S. Patent 12,492,253, which covers Xencor’s Xtend Fc domain for extending the half-life of antibodies targeting C5, wi...

Analyst ratings

93%

of 14 ratings
Buy
92.9%
Hold
7.1%
Sell
0%

People also own

Based on the portfolios of people who own XNCR. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.